Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study
NCT ID: NCT00567788
Last Updated: 2007-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2006-07-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At the Baseline visit and last visit of each Treatment period (Day 0, 42 and 84), IOP will be measured at 9 am and 5 pm. On Day 14 and 56, IOP will be measured only at 9 AM.
Thus, when the IOP is measured in the clinic at 9 AM, approximately 13 hours would have elapsed from the evening dose. This will coincide with the approximate peak effect of bimatoprost and latanoprost. The IOP reading at 5 PM will be the approximate trough for latanoprost and bimatoprost.
The IOP at the end of each Treatment period at 6 weeks (Day 42 and 84) will be utilized as the primary endpoint and a comparison of mean IOPs of the two treatment groups compared with the baseline (Day 0). For those who do not, for any reason, complete the 6-week assessment, their last IOP measure will be carried forward to provide the endpoint. However, the number of such cases within each treatment group will also be reported.
Prior to the trial, all patients will undergo clinical examinations and eye tests to determine eligibility.
After being enrolled into the trial, patients will be randomized to receive either latanoprost or bimatoprost. They will be subjected to a list of tests (details of schedule and procedures in Appendix A) on the baseline day (Day 0) and instructed that the first eye application will start at 8pm on the same day. For 6 weeks, patients assigned to the latanoprost treatment group will administer latanoprost 0.005% in the evening. Patients assigned to the bimatoprost group will administer 0.03% bimatoprost once daily (in the evening). Study visits will be on Day 14 (Visit 2) and Day 42 (Visit 3).
After 6 weeks, patients will be crossed over to the other medication. Patients will undergo exactly the same regimen of examination and clinic visits as in Treatment period I. Study visits will be on Day 56 (Visit 4) and Day 84 (Visit 5).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
Latanoprost-Bimatoprost
latanoprost 0.005% once daily followed by bimatoprost 0.03%
2
Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
Bimatoporost-Latanoprost
bimatoprost 0.03% once daily followed by latanoprost 0.005%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Latanoprost-Bimatoprost
latanoprost 0.005% once daily followed by bimatoprost 0.03%
Bimatoporost-Latanoprost
bimatoprost 0.03% once daily followed by latanoprost 0.005%
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age more than or equal to 40 years old
3. Informed consent obtained at pre-study visit for all patients
Exclusion Criteria
2. One eye eligible and fellow eye on unsuitable glaucoma treatment for this trial
3. IOP \> 36 mmHg at Pre-study visit
4. Advanced glaucoma at risk of progression. This is defined as vertical cup-disc ratio \> 0.9 and/or central visual field loss with a sensitivity of \< 10 dB in any of the 4 visual field test points closest to fixation
5. Ocular infection or inflammation (except when related to peripheral iridotomy) within 3 months of the prestudy visit
6. On more than two anti-glaucoma medications
7. Previous intraocular surgery apart from laser peripheral iridotomy
8. Previous trauma to the eye, with angle damage
9. Ocular treatment with a steroid or non-steroidal anti-inflammatory medication within 1 month of the prestudy visit.
10. Use of contact lens.
11. Cornea infection or other cornea abnormalities.
12. Ocular diseases such as dry eye or retinal pathology.
13. Oral medications, such as diuretics, known to affect IOP.
14. Cerebrovascular, hepatic, renal, metabolic disease.
15. Known allergy to benzalkonium, or any other components of latanoprost/bimatoprost.
16. History of non-compliance.
17. Women who are pregnant, lactating, or of childbearing potential and not using adequate contraception.
18. Participated in another therapeutic medication study within the last 1 month.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Singapore National Eye Centre
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Singapore National Eye Centre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tin Aung
Role: PRINCIPAL_INVESTIGATOR
SNEC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Singapore National Eye Centre
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SQGL08
Identifier Type: -
Identifier Source: secondary_id
R353/11/2004
Identifier Type: -
Identifier Source: org_study_id